EA200400793A1 - Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции - Google Patents

Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции

Info

Publication number
EA200400793A1
EA200400793A1 EA200400793A EA200400793A EA200400793A1 EA 200400793 A1 EA200400793 A1 EA 200400793A1 EA 200400793 A EA200400793 A EA 200400793A EA 200400793 A EA200400793 A EA 200400793A EA 200400793 A1 EA200400793 A1 EA 200400793A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
norepinefrin
application
cognitive function
reverse capture
Prior art date
Application number
EA200400793A
Other languages
English (en)
Russian (ru)
Inventor
Фрэнклин Портер Баймастер
Дональд Ричард Гелерт
Дэвид Ли Маккинзи
Чарльз Ренкин Янг
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200400793A1 publication Critical patent/EA200400793A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA200400793A 2001-12-11 2002-11-27 Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции EA200400793A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11
PCT/US2002/036132 WO2003049724A1 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Publications (1)

Publication Number Publication Date
EA200400793A1 true EA200400793A1 (ru) 2004-10-28

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400793A EA200400793A1 (ru) 2001-12-11 2002-11-27 Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции

Country Status (26)

Country Link
US (1) US20050009925A1 (https=)
EP (1) EP1458368B1 (https=)
JP (1) JP2005517647A (https=)
KR (1) KR20040066895A (https=)
CN (1) CN1713900A (https=)
AU (1) AU2002352625A1 (https=)
BR (1) BR0213581A (https=)
CA (1) CA2467802A1 (https=)
CO (1) CO5590907A2 (https=)
CZ (1) CZ2004709A3 (https=)
DE (1) DE60223718T2 (https=)
EA (1) EA200400793A1 (https=)
EC (1) ECSP045145A (https=)
ES (1) ES2295435T3 (https=)
HR (1) HRPK20040528B3 (https=)
HU (1) HUP0402619A3 (https=)
IL (1) IL161989A0 (https=)
MX (1) MXPA04005716A (https=)
MY (1) MY136367A (https=)
NO (1) NO20042904L (https=)
NZ (1) NZ532065A (https=)
PL (1) PL369311A1 (https=)
SK (1) SK2442004A3 (https=)
TW (1) TW200300672A (https=)
WO (1) WO2003049724A1 (https=)
ZA (1) ZA200404274B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1530476A1 (en) * 2002-08-14 2005-05-18 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of hot flashes
EP1708717B1 (en) * 2003-07-28 2011-10-05 Leslie Joe Dunaway Atomoxetine for treatment of allergic rhinitis and asthma
EP1660064A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
EP1729754B1 (en) * 2003-12-12 2008-07-02 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes
BRPI0510453A (pt) * 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317730A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Treatment for menopausal and perimenopausal vasomotor symptons
WO2011014475A2 (en) * 2009-07-31 2011-02-03 National Taiwan University Treating negative symptoms of schizophrenia associated with defective neuregulin 1
JP6126531B2 (ja) * 2011-10-03 2017-05-10 国立研究開発法人国立長寿医療研究センター タウ凝集阻害剤
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US6465458B1 (en) * 1999-07-01 2002-10-15 Pharmacia & Upjohn Company Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor
AP2002002481A0 (en) * 1999-10-13 2002-06-30 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors.
AU2002243451A1 (en) * 2001-01-02 2002-07-16 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション

Also Published As

Publication number Publication date
BR0213581A (pt) 2004-08-24
CA2467802A1 (en) 2003-06-19
DE60223718D1 (de) 2008-01-03
US20050009925A1 (en) 2005-01-13
ECSP045145A (es) 2004-07-23
KR20040066895A (ko) 2004-07-27
DE60223718T2 (de) 2008-10-30
ZA200404274B (en) 2005-09-13
HRPK20040528B3 (en) 2006-03-31
CZ2004709A3 (cs) 2004-10-13
AU2002352625A1 (en) 2003-06-23
EP1458368A1 (en) 2004-09-22
HUP0402619A2 (hu) 2005-03-29
TW200300672A (en) 2003-06-16
JP2005517647A (ja) 2005-06-16
SK2442004A3 (en) 2004-12-01
MXPA04005716A (es) 2004-12-06
CO5590907A2 (es) 2005-12-30
WO2003049724A1 (en) 2003-06-19
NO20042904L (no) 2004-09-07
EP1458368B1 (en) 2007-11-21
ES2295435T3 (es) 2008-04-16
NZ532065A (en) 2007-03-30
HRP20040528A2 (en) 2004-10-31
IL161989A0 (en) 2005-11-20
CN1713900A (zh) 2005-12-28
PL369311A1 (en) 2005-04-18
HUP0402619A3 (en) 2008-04-28
MY136367A (en) 2008-09-30

Similar Documents

Publication Publication Date Title
EA200400793A1 (ru) Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции
BR0206422B1 (pt) mÉtodo e instalaÇço industrial para espessamento de lamas derivadas de tratamento de Águas atravÉs de floculaÇço-decantaÇço com floco lastreado.
EA200501251A1 (ru) Антинеопластические комбинации
NO20035609D0 (no) Fremgangsmåte for kontinuerlig naftabehandling
EP1463531A4 (en) PROCESS FOR INHIBITING OKULAR PROCESSES
DE60101265D1 (de) Behandlung von augenschmerzen
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
EE200400005A (et) Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine
DE60220043D1 (de) Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen
DE60221670D1 (de) Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
NL1021504A1 (nl) Waterstofbehandelingsproces.
EA200600896A1 (ru) Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря
DK1408976T5 (da) Behandling af ADHD (Attention deficit hyperactivity disorder)
EP1359885A4 (en) NOS-HEMMER FOR THE TREATMENT OF WRINKLES
ATE359783T1 (de) Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems
PT102870A (pt) Metodo de tratamento de condensados
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
WO2002040006A3 (en) Treatment of anxiety disorders
FI20040531A7 (fi) Insuliiniresistenttien tilojen hoitaminen ja diagnosointi
EA200301299A1 (ru) Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс
EA200501259A1 (ru) Комбинированное применение фибрата и орлистата для лечения ожирения
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser